Duell, Eric J.Lujan-Barroso, LeilaSala, NuriaMcElyea, Samantha DeitzOvervad, KimTjonneland, AnneOlsen, AnjaWeiderpass, ElisabeteBusund, Lill-ToveMoi, LineMuller, DavidVineis, PaoloAune, DagfinnMatullo, GiuseppeNaccarati, AlessioPanico, SalvatoreTagliabue, GiovannaTumino, RosarioPalli, DomenicoKaaks, RudolfKatzke, Verena A.Boeing, HeinerH.B.(as), Bueno-de-MesquitaPeeters, Petra H.Trichopoulou, AntoniaLagiou, PagonaKotanidou, AnastasiaTravis, Ruth C.Wareham, NickKhaw, Kay-TeeQuiros, Jose RamonRodriguez-Barranco, MiguelDorronsoro, MirenChirlaque, Maria-DoloresArdanaz, EvaSeveri, GianlucaBoutron-Rault, Marie-ChristineRebours, VincianeBrennan, PaulGunter, MarcScelo, GhislaineCote, GregSherman, StuartKorc, Murray2019-04-302019-04-302017-09-01Duell, E. J., Lujan-Barroso, L., Sala, N., Deitz McElyea, S., Overvad, K., Tjonneland, A., … Korc, M. (2017). Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. International journal of cancer, 141(5), 905–915. doi:10.1002/ijc.30790https://hdl.handle.net/1805/18996Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p).en-USPublisher PolicyBiomarkersCohort studiesmicroRNAsPancreatic cancerArticle